A GABAB agonist reverses the behavioral sensitization to morphine in rats

被引:20
作者
Bartoletti, Marci [1 ]
Ricci, Francesca [1 ]
Gaiardi, Margherita [1 ]
机构
[1] Univ Bologna, Dept Pharmacol, I-40126 Bologna, Italy
关键词
sensitization; desensitization; locomotor activity; GABA(B) receptor; morphine; baclofen; rat;
D O I
10.1007/s00213-006-0693-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale In laboratory animals, repeated administration of drugs of abuse causes sensitization to their stimulant and rewarding effects. Neuroadaptations underlying sensitization could be related to those that contribute to addictive behaviors. An increased understanding of the molecular mechanisms of sensitization could lead to improved treatments for addiction. Objectives Since baclofen (BCF) co-administration has been reported to block the development and the expression of motor sensitization to morphine (MOR), the present study examined the hypothesis that a chronic treatment with BCF alone might reverse and/or prevent MOR-induced sensitization. Methods Rats were first sensitized to MOR (saline or 10 mg/kg MOR i.p.; days 1-10) and then chronically treated with BCF (saline or 2 mg/kg BCF i.p.; days 11-20). Finally, the motility effect of MOR (10 mg/kg i.p.) was assessed 3 and 30 days after the end of BCF treatment. The same rats were again challenged with MOR on day 70, after a further period of saline or MOR treatment (days 51-60). Results Behavioral sensitization to MOR was observed in control animals but not in rats chronically treated with BCF (days 23 and 50). Thus, BCF completely reversed MOR-induced sensitization, and its effect was long lasting. However, a previous repeated BCF treatment did not prevent the development of sensitization to MOR both in naive and desensitized rats. Conclusions The present results confirm that gamma-aminobutyric acid (GABA)(B) receptors play an important role in the expression of motor sensitization to MOR and suggest that GABA(B) agonists could be useful for reversing the neuroadaptations related to drug addiction.
引用
收藏
页码:79 / 85
页数:7
相关论文
共 47 条
[1]   DOSE-TIME MOTILITY EFFECTS OF MORPHINE AND METHADONE IN NAIVE OR MORPHINIZED RATS [J].
BABBINI, M ;
GAIARDI, M ;
BARTOLETTI, M .
PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1979, 11 (09) :809-816
[2]   PERSISTENCE OF CHRONIC MORPHINE EFFECTS UPON ACTIVITY IN RATS 8 MONTHS AFTER CEASING TREATMENT [J].
BABBINI, M ;
GAIARDI, M ;
BARTOLETTI, M .
NEUROPHARMACOLOGY, 1975, 14 (08) :611-614
[3]   Baclofen blocks the development of sensitization to the locomotor stimulant effect of amphetamine [J].
Bartoletti, M ;
Gubellini, C ;
Ricci, F ;
Gaiardi, M .
BEHAVIOURAL PHARMACOLOGY, 2005, 16 (07) :553-558
[4]   The GABAB agonist baclofen blocks the expression of sensitisation to the locomotor stimulant effect of amphetamine [J].
Bartoletti, M ;
Gubellini, C ;
Ricci, F ;
Gaiardi, M .
BEHAVIOURAL PHARMACOLOGY, 2004, 15 (5-6) :397-401
[5]   LONG-TERM SENSITIZATION TO THE EXCITATORY EFFECTS OF MORPHINE - A MOTILITY STUDY IN POST-DEPENDENT RATS [J].
BARTOLETTI, M ;
GAIARDI, M ;
GUBELLINI, G ;
BACCHI, A ;
BABBINI, M .
NEUROPHARMACOLOGY, 1983, 22 (10) :1193-1196
[6]   CROSS-SENSITIZATION TO THE EXCITATORY EFFECT OF MORPHINE IN POST-DEPENDENT RATS [J].
BARTOLETTI, M ;
GAIARDI, M ;
GUBELLINI, C ;
BACCHI, A ;
BABBINI, M .
NEUROPHARMACOLOGY, 1985, 24 (09) :889-893
[7]   AN ANALYSIS OF TRANSFORMATIONS [J].
BOX, GEP ;
COX, DR .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1964, 26 (02) :211-252
[8]   Attenuation of d-amphetamine self-administration by baclofen in the rat:: behavioral and neurochemical correlates [J].
Brebner, K ;
Ahn, S ;
Phillips, AG .
PSYCHOPHARMACOLOGY, 2005, 177 (04) :409-417
[9]   A potential role for GABAB agonists in the treatment of psychostimulant addiction [J].
Brebner, K ;
Childress, AR ;
Roberts, DCS .
ALCOHOL AND ALCOHOLISM, 2002, 37 (05) :478-484
[10]   The GABAB antagonist CGP56433A attenuates the effect of baclofen on cocaine but not heroin self-administration in the rat [J].
Brebner, K ;
Froestl, W ;
Roberts, DCS .
PSYCHOPHARMACOLOGY, 2002, 160 (01) :49-55